CD8A and neoplasm: In conclusion, TTFields promote ICD of tumor cells, and when delivered concomitantly with ICI may augment the immune response, via higher tumor infiltration, IFN-γ production, and development of effector memory CD8+ T cells, promoting anti-tumor immunity, and resulting in improved tumor control.